XML 58 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 1,331.2 $ 2,913.7
Marketable securities 1,278.9 1,562.2
Accounts receivable, net 1,913.8 1,880.5
Due from anti-CD20 therapeutic programs 413.5 590.2
Inventory 1,068.6 804.2
Other current assets 881.1 631.0
Total current assets 6,887.1 8,381.8
Marketable securities 772.1 1,408.1
Property, plant and equipment, net 3,411.5 3,247.3
Operating lease assets 433.3 427.0
Intangible assets, net 3,084.3 3,527.4
Goodwill 5,762.1 5,757.8
Deferred tax asset 1,369.5 3,232.1
Investments and other assets 2,899.0 1,252.8
Total assets 24,618.9 27,234.3
Current liabilities:    
Current portion of notes payable 0.0 1,495.8
Taxes payable 142.0 71.4
Accounts payable 454.9 530.8
Accrued expenses and other 3,145.3 2,765.8
Total current liabilities 3,742.2 4,863.8
Notes payable 7,426.2 4,459.0
Deferred tax liability 1,032.8 2,810.8
Long-term operating lease liabilities 402.0 412.7
Other long-term liabilities 1,329.6 1,348.9
Total liabilities 13,932.8 13,895.2
Commitments, contingencies and guarantees (Notes 21 and 22)
Biogen Inc. shareholders’ equity    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 0.0 0.0
Accumulated other comprehensive loss (299.0) (135.2)
Retained earnings 13,976.3 16,455.4
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively (2,977.1) (2,977.1)
Total Biogen Inc. shareholders’ equity 10,700.3 13,343.2
Noncontrolling interests (14.2) (4.1)
Total equity 10,686.1 13,339.1
Total liabilities and equity $ 24,618.9 $ 27,234.3